Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA fiscal 1997 budget

This article was originally published in The Tan Sheet

Executive Summary

FDA fiscal 1997 budget: OTC and Rx drugs would receive $273.9 mil. under House Appropriations/agriculture subcommittee bill, unchanged from the Administration's FY 1997 budget proposal. The subcommittee marked up its agriculture appropriations bill, which includes FDA funding, May 30. Under the measure, funding for FDA's foods programs would remain flat at $221.6 mil. -- a $3.8 mil. reduction from the president's request. Overall FDA funding of $920.9 is recommended by the House subcommittee, marking a compromise between the Administration's $924.7 mil. proposal and the $917.7 mil. fiscal 1996 level. Unauthorized user fees for foods and medical devices, which totaled $39 mil. in the president's request, are dropped in the House measure, although the bill retains Rx drug and mammography clinics user fees. During the markup, subcommittee member Rep. Jim Walsh (R-N.Y.) suggested adding report language requiring FDA to meet its user fee deadlines. The House Appropriations Committee is expected to mark up the bill on June 6...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel